Companies Dominating the Biosimilars Landscape
- Biocon Limited
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Novartis AG
- Intas Pharmaceuticals Ltd.
- BioXpress Therapeutics SA
- Genor Biopharma Co. Ltd
- Allergan plc (AbbVie Inc.)
- Coherus BioSciences, Inc.
- Pfizer Inc.
- Reliance Life Sciences Private Limited
Browse Key Market Insights with Data Illustration:
In the News
-
Biocon Limited - Abevmy (bBevacizumab) is now available in Canada. It is co-developed by Biocon Biologics (a subsidiary of Biocon Limited) and Viatris and is a biosimilar to Roche’s Avastin (Bevacizumab). Health Canada has approved the drug for four oncology indications.
-
Amgen Inc., - announced the approval of RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab) by the U.S. Food and Drug Administration (FDA). It is used for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA).
